Amendment #42 to H4891

Assess the Feasibility of In-State Drug Manufacturing

Ms. Decker of Cambridge moves to amend the amendment by adding the following section:

"SECTION XXXX.

There shall be a commission to investigate and assess the feasibility of in-state drug manufacturing.

The commission shall consist of: 1 of whom shall be the secretary of health and human services, or a designee; 1 of whom shall be the commissioner of insurance, or a designee; 1 of whom shall be a representative of the Center for Health Information and Analysis; 1 of whom shall be a representative of the Health Policy Commission; 1 of whom is a representive of the Massachsetts Health and Hospital Association; 1 of whom shall be a representative of the division of insurance; 1 of whom shall be an individual involved in biomedical research; 1 of whom shall be a representative of the board of registration in pharmacy; 1 physician licensed to practice within the Commonwealth having expertise in the treatment of diabetes and related complications; 1 physician licensed to practice within the Commonwealth having expertise in the treatment of substance use disorders and related complications; 1 physician licensed to practice within the Commonwealth having expertise in the treatment of allergic reactions and related complications; 1 physician licensed to practice within the Commonwealth having expertise in the treatment of asthma and related complications; and 1 hospital pharmacist.

The commission shall study and report on the feasibility of in-state drug manufacturing in the Commonwealth. The commission shall: (i) study the feasibility of manufacturing commonly used pharmaceutical products and their analogs, including but not limited to insulin, naloxone, albuterol inhalers, and epinephrine; (ii) assess the feasibility of providing the drug and drug analogs produced to low-income residents of the Commonwealth at low or no cost through hospitals, pharmacies, and health care providers in the Commonwealth or at a reduced cost on a means-tested basis; (iii) assess the feasibility of partnerships between the state and other entities, including but not limited to, public universities and existing drug manufacturers or through other appropriate institutions and a licensed drug manufacturer, to leverage existing research and manufacturing capacity (iv) study the example of state of California’s in-state drug manufacturing initiative, and (v) issue a report on the commission’s findings and policy recommendations.

In its assessment, the commission shall consider various factors including: (i) the number of low-income residents of in-state manufacturing who currently require the drugs listed in subsection (c); (ii) the ability of the public university system or other appropriate entity by itself, in partnership with another appropriate institution or through a public-private partnership with a licensed drug manufacturer to produce insulin and insulin analogs in an amount sufficient to fulfill the needs of low-income residents of the Commonwealth who require any of the drugs listed in subsection (c); (iii) any long-term cost savings and revenue generation for the Commonwealth and the public university system or other appropriate entity; (iv) any long-term cost savings and other benefits to low-income residents of the Commonwealth who would receive insulin and insulin analogs at low or no cost; (v) any costs to the public university system or other appropriate entity and to the Commonwealth to produce and the drugs listed in subsection (c), including additional administrative costs; (vi) state and federal regulatory or legal obstacles, including requirements for licensure, to the production and distribution of the drugs listed in subsection (c) and analogs within the Commonwealth by the public university system or other appropriate institutions; (vii) available alternative methods for providing the drugs listed in subsection (c) to low-income residents of the Commonwealth at low or no cost; (viii) options for capping copayments for the drugs listed in subsection (c) or analogs provided through private insurers; (ix) the potential for the Commonwealth to engage in volume purchasing of the drugs listed in subsection (c) at reduced cost; (x) the mechanisms by which the Commonwealth could establish a program to distribute the drugs listed in subsection (c) and analogs to residents of the Commonwealth; (xi) opportunities to establish an interstate compact with other New England states to reduce of drugs listed in subsection (c) and their analog costs in compact states; (xii) opportunities to establish a public entity to manage the purchasing and distribution of of drugs listed in subsection (c) and their analogs with the possibility of eventual transition to a private entity; (xiii) opportunities to establish a model facility to affordably manufacture the drugs listed in subsection (c) and analogs and to distribute of drugs listed in subsection (c) and their analogs to residents of the Commonwealth; and (xiv) opportunities to procure dedicated funding to support the manufacture of the drugs listed in subsection (c) and their analogs and the distribution of drugs listed in subsection (c) and their analogs to residents of the Commonwealth.

Not later than September 1, 2025, the commission shall submit its report to the clerks of the senate and house of representatives, the joint committee on health care financing and the joint committee on public health.


Additional co-sponsor(s) added to Amendment #42 to H4891

Assess the Feasibility of In-State Drug Manufacturing

Representative:

Mindy Domb

Mike Connolly